With a large genome-wide association study, researchers identified several significant associations in PDE4B, a gene with expression shifts in brain samples from stressed mice.
MammaPrint classifies patients as either high risk or low risk of recurrence over a 10-year period while BluePrint classifies patients by breast cancer subtype.
An international team of researchers conducted a set of genome-wide association studies and other analyses using both human host and S. pneumoniae samples.
A LIMS1 gene variant appeared to coincide with increased risk of allograft rejection in kidney transplant recipients.
The company is seeing increasing interest in its GeoMx platform with numerous studies from early users presented last month at AACR.
The company reported total revenues of $27.7 million, with growth in its consumables business but a drop in instrument revenues from the prior year's first quarter.
The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
The startup will sell tools and services based on the Nucleic Acid Programmable Protein Array technology developed by Biodesign researcher Joshua LaBaer.
Most head and neck cancer patients saw a decline in oral HPV DNA after treatment, but those who did not were more likely to experience disease recurrence.
The firm is using a microarray-based platform as part of a laboratory-based test to diagnose different types of stroke from blood samples.
A GWAS involving more than 50,000 cases and controls revealed 10 known and 20 new risk loci, including loci with apparent ties to disease subtypes.
Agilent has agreed to provide customized high-fidelity oligo microarrays for the nucleic acid detection step in SomaLogic's Somascan assay.
The in vitro diagnostic is designed to detect whole gene segments for influenza A and B viruses and can characterize viruses as seasonal or nonseasonal.
Illumina said that the DTC market is in "transition" from ancestry and genealogy to one driven by demand for health information.
The recently launched system can measure the concentration and size of extracellular vesicles as small as 50 nanometers and requires no sample preparation.
The firm will work with investigators from the University of North Carolina at Chapel Hill and the University of Virginia to validate its AIR system in CRISPR workflows.
Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.
While the study didn't meet its primary endpoint, it showed the potential of transcriptomics to match cancer patients to beneficial treatments.
Under the terms of the settlement, Enzo Life Sciences will receive $14 million in exchange for granting global licenses to Hologic and Grifols.
The test completes a suite of assays designed to detect pathogens that can cause sepsis using the firm's ePlex system.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.